C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer
Canadian Urological Association Journal · 16.03.2026 · 20 (7)
DOI: 10.5489/cuaj.9414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Urological Association Journal, online erschienen am 16.03.2026. Verfasst von Ahmet Alper Özdeş und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Karakoçan State Hospital, Elazığ, Turkey. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Systemic inflammation and nutritional status influence prostate cancer out-comes. The C-reactive protein-albumin-lymphocyte (CALLY) index integrates these param-eters, but its ability to predict biochemical recurrence (BCR) is not well-established.
Methods
In a single-center, retrospective cohort of 600 patients (2018–2022), the pre-treatment CALLY index was calculated as [albumin (g/dL) × lymphocytes (cells/μL)]/[CRP (mg/dL) × 10^4]. Patients were stratified by D’Amico risk. BCR was defined as prostate-specific antigen (PSA) ≥0.2 ng/mL after radical prostatectomy (confirmed) or ≥2.0 ng/mL above nadir after radiotherapy. Kaplan-Meier and Cox models evaluated associations; model performance was assessed using receiver operating curve (ROC), C-index, net reclassifica-tion improvement (NRI), and decision-curve analysis (DCA).
Results
Over a median followup of 28.4 months, 26.8% developed BCR. The optimal CAL-LY threshold was 1524.2, demonstrating modest discriminative ability (area under the curve [AUC] 0.684, 95% confidence interval [CI] 0.624–0.744; sensitivity 72.4%, specificity 64.8%). Low CALLY was associated with higher 36-month BCR rates (31.4% vs. 21.6%; log-rank p=0.042). In multivariable analysis, CALLY independently predicted BCR both as a continuous measure (per 100-unit increase: HR 0.882, 95% CI 0.778–0.998, p=0.048) and dichotomized at the median (HR 0.798, 95% CI 0.642–0.992, p=0.042), alongside baseline PSA and Gleason ≥4+4. Adding CALLY modestly improved discrimination of CAPRA (C-index 0.71→0.74) and Memorial Sloan Kettering Cancer Center (MSKCC) (0.73→0.76) models, with NRI 0.246 (p=0.006) and net clinical benefit on DCA across 10–40% thresh-olds. Effects were most pronounced in high-risk and surgically treated patients.
Conclusions
The pre-treatment CALLY index represents a readily available biomarker that independently predicts BCR and may complement established risk stratification tools in prostate cancer, although model performance was modest. External validation in prospective cohorts with longer followup is necessary before clinical implementation.
Autor:innen und Institutionen
- Department of Urology, Karakoçan State Hospital, Elazığ, Turkey.
- Departmentof Urology, Malatya Education and Research Hospital, Malatya, Turkey.
- Department of Urology, Mersin University Hospital, Mersin, Turkey.
- Department of Urology, Fırat University Hospital, Elazığ, Turkey.
Zitieren
APA
Özdeş, A. A., Sesli, M., Başaranoğlu, M., Karakeçi, A., Orhan, İ., & Akbay, E. (2026). C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer. Canadian Urological Association Journal, 20(7). https://doi.org/10.5489/cuaj.9414
Vancouver
Özdeş AA, Sesli M, Başaranoğlu M, Karakeçi A, Orhan İ, Akbay E. C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer. Canadian Urological Association Journal. 2026;20(7). doi:10.5489/cuaj.9414
BibTeX
@article{zde2026,
author = {Özdeş, Ahmet Alper and Sesli, Mustafa and Başaranoğlu, Mert and Karakeçi, Ahmet and Orhan, İrfan and Akbay, Erdem},
title = {C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer},
journal = {Canadian Urological Association Journal},
year = {2026},
volume = {20},
number = {7},
doi = {10.5489/cuaj.9414}
}
EUVIMED